Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy

[1]  Erkko Ylösmäki,et al.  Design and application of oncolytic viruses for cancer immunotherapy. , 2019, Current opinion in biotechnology.

[2]  D. Karlis,et al.  Efficacy of Adoptive Therapy with Tumor-infiltrating Lymphocytes and Recombinant Interleukin-2 in Advanced Cutaneous Melanoma: A Systematic Review and Meta-analysis. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Q. Gao,et al.  PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma , 2019, Journal of Immunotherapy for Cancer.

[4]  G. Kroemer,et al.  Effects of interleukin-2 in immunostimulation and immunosuppression , 2019, The Journal of experimental medicine.

[5]  D. Bartlett,et al.  Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics , 2019, Journal of Immunotherapy for Cancer.

[6]  Z. Guo,et al.  Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2 , 2018, Nature Communications.

[7]  D. Bartlett,et al.  Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  R. Fouchier,et al.  Armed oncolytic viruses: A kick-start for anti-tumor immunity , 2018, Cytokine & Growth Factor Reviews.

[9]  G. Kroemer,et al.  Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies , 2018, Oncoimmunology.

[10]  U. Kammula,et al.  Metastasectomy for Tumor-Infiltrating Lymphocytes: An Emerging Operative Indication in Surgical Oncology , 2017, Annals of Surgical Oncology.

[11]  J. Maher,et al.  Prospects for combined use of oncolytic viruses and CAR T-cells , 2017, Journal of Immunotherapy for Cancer.

[12]  C. Bollard,et al.  Virus-Specific T Cells for the Immunocompromised Patient , 2017, Front. Immunol..

[13]  Michael E. Lassman,et al.  Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy , 2017, Cell.

[14]  Laurence Zitvogel,et al.  The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.

[15]  S. Hervás-Stubbs,et al.  Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy. , 2017, Cancer research.

[16]  A. K. Srivastava,et al.  Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. , 2017, The Lancet. Oncology.

[17]  Z. Guo,et al.  Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy , 2017, Nature Communications.

[18]  Yaohe Wang,et al.  The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model , 2016, Clinical Cancer Research.

[19]  T. Jiang,et al.  Role of IL-2 in cancer immunotherapy , 2016, Oncoimmunology.

[20]  Shari Pilon-Thomas,et al.  Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy , 2016, PloS one.

[21]  M. Donia,et al.  Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen , 2016, Clinical Cancer Research.

[22]  F. Marincola,et al.  Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. , 2015, The Journal of clinical investigation.

[23]  Z. Guo,et al.  CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy , 2015, Oncoimmunology.

[24]  C. Meijer,et al.  Extent and Location of Tumor-Infiltrating Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome to Adjuvant Active Specific Immunotherapy , 2015, Clinical Cancer Research.

[25]  Yiping Yang,et al.  Cancer immunotherapy: harnessing the immune system to battle cancer. , 2015, The Journal of clinical investigation.

[26]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[27]  D. Gilham,et al.  Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma , 2015, British Journal of Cancer.

[28]  Xiaoliu Zhang,et al.  An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites , 2014, Oncotarget.

[29]  T. Hagemann,et al.  A Vaccinia Virus Armed with Interleukin-10 Is a Promising Therapeutic Agent for Treatment of Murine Pancreatic Cancer , 2014, Clinical Cancer Research.

[30]  C. Guerra,et al.  Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation. , 2014, Cancer research.

[31]  G. Coukos,et al.  T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. , 2014, Cancer discovery.

[32]  D. Bartlett,et al.  Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity , 2014, Front. Oncol..

[33]  Pierre Validire,et al.  Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. , 2014, Cancer research.

[34]  S. Nimmagadda,et al.  The intricate role of CXCR4 in cancer. , 2014, Advances in cancer research.

[35]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[36]  D. Bartlett,et al.  Oncolytic viruses as therapeutic cancer vaccines , 2013, Molecular Cancer.

[37]  W. Gong,et al.  Isolation of Mouse Tumor-Infiltrating Leukocytes by Percoll Gradient Centrifugation , 2013 .

[38]  M. Bloomston,et al.  Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer , 2013, Nature Medicine.

[39]  T. Waldmann,et al.  Superior T memory stem cell persistence supports long-lived T cell memory. , 2013, The Journal of clinical investigation.

[40]  J. Flynn,et al.  Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. , 2012, Cancer research.

[41]  S. Rosenberg,et al.  Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice , 2011, Clinical Cancer Research.

[42]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[43]  Z. Guo,et al.  Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[44]  I. Endo,et al.  FOXP3+ Regulatory T Cells and Tumoral Indoleamine 2,3-Dioxygenase Expression Predicts the Carcinogenesis of Intraductal Papillary Mucinous Neoplasms of the Pancreas , 2010, Pancreatology.

[45]  Z. Guo,et al.  The Combination of Immunosuppression and Carrier Cells Significantly Enhances the Efficacy of Oncolytic Poxvirus in the Pre-Immunized Host , 2010, Gene Therapy.

[46]  S. Kim-Schulze,et al.  Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma , 2010, Annals of Surgical Oncology.

[47]  C. Turtle,et al.  Adoptive transfer of virus-specific and tumor-specific T cell immunity. , 2009, Current opinion in immunology.

[48]  S. Qiu,et al.  Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma , 2009, Clinical Cancer Research.

[49]  F. Errington,et al.  Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity , 2008, Clinical Cancer Research.

[50]  F. Tangy,et al.  Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. , 2008, Cancer research.

[51]  Zihua Zeng,et al.  Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses. , 2007, Cancer research.

[52]  Zhao-You Tang,et al.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  M. Azuma,et al.  Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer , 2007, Clinical Cancer Research.

[54]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[55]  Stefan Schneeberger,et al.  Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[57]  Bjoern Peters,et al.  HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[58]  J. Jacobs,et al.  Local interleukin 2 therapy is most effective against cancer when injected intratumourally , 2005, Cancer Immunology, Immunotherapy.

[59]  S. Libutti,et al.  Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. , 2001, Cancer research.

[60]  R. Martuza,et al.  Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. , 1999, Human gene therapy.

[61]  S. Rosenberg,et al.  High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. , 1999, Journal of immunology.